To provide the information your oncologist is not telling you or doesn't have the time to!
Here, we delve into the dynamic world of cutting-edge cancer treatments and therapies. Stay informed about groundbreaking advancements in cancer care, from emerging therapies to novel treatment modalities. Discover how science and technology are shaping the future of oncology, offering new hope and possibilities to those affected by cancer. Join us as we explore innovative approaches that hold the promise of brighter tomorrows for patients and their families.
by Sajeve Thomas, MD, Oncologist Biliary tract cancer (BTC), a rare and aggressive form of cancer affecting the bile ducts, gallbladder, and liver, has historically been challenging to treat. However, there is hope on the horizon with the recent FDA approval of pembrolizumab (Keytruda, Merck) in combination with chemotherapy. This groundbreaking development offers new possibilities …
On November 7, 2023, the Food and Drug Administration (FDA) made significant updates to the existing indication of pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. These changes come as part of the FDA’s commitment to advancing cancer treatment options, bringing …
Shifting the Paradigm of Cancer Treatment In previous posts on MedOncMD.com, I’ve discussed a message about a future where we rely less on traditional chemotherapy. Dr. Thomas and I have dedicated a significant portion of our careers to shifting the paradigm toward more targeted therapies that minimize damage to healthy cells. Our ultimate goal is …
Traditional Treatment Approaches for Hodgkin’s Lymphoma Lymphomas encompass a diverse group of blood cancers, with various types and treatment approaches depending on factors such as lymphoma subtype, origin, and aggressiveness. One particular lymphoma subtype with unique treatment options is Hodgkin’s lymphoma. Traditionally, in the United States, Hodgkin’s lymphoma has been treated with a chemotherapy combination …
In terms of cancer diagnoses, the more common ones we hear of are cancers such as Leukemia, Lymphoma, melanoma, and breast cancer. But what about Leiomyosarcoma?
Leiomyosarcoma is a rare and aggressive form of cancer that develops in the smooth muscles of the body (i.e. intestines, stomach, uterus, blood vessels).
One of the most vivid metaphors for chemotherapy is that of a bomb: it obliterates both good and bad cells, with the hope that only the good ones regenerate. While traditional chemotherapy remains a significant tool in cancer treatment, there’s been a recent shift towards more precise therapies that selectively target cancer cells. In the …
Article written by one of our Melanoma/Sarcoma Clinical Trial Coordinators Chloe Caldwell to a target audience of healthcare providers regarding a new ongoing protocol for patients dealing with GIST open globally and at the Orlando Health Cancer Institute. All information posted here is publicly available here. Gastrointestinal Stromal Tumors (GIST) constitute a category of soft …
ASCO 2023 was an incredible conference and I had completely enjoyed the networking, presentations, and evening meetings. Here are two melanoma clinical trials that we had also participated in enrollment at the Orlando Health Cancer Institute. It is incredibly exciting to see patients do better with improved responses as well as improved odds of not …
ASCO 2023 was a ton of fun and lot of learning. In the coming weeks, I’ll share select abstracts that I thought were most important. This article discusses data from a groundbreaking PROSPECT trial which was presented as a Plenary topic at Chicago and published in NEJM last week. Ultimately, this creates more treatment options …
Colon cancer is the third most common cancer worldwide, affecting millions of individuals every year. Currently, the treatment paradigm for resected stage 2 and 3 colon cancer patients typically involves surgery followed by adjuvant chemotherapy to reduce the risk of cancer recurrence. However, the prognosis for these patients varies significantly, with some experiencing a complete …